<DOC>
	<DOCNO>NCT00932412</DOCNO>
	<brief_summary>This study phase II randomize multicenter study . Patients enrol time diagnosis receive one two cycle induction chemotherapy . Patients , without indication intensification allogeneic stem cell transplantation and/or without HLA ( Human Leukocyte Antigen ) -compatible donor , attain CR one two cycle induction chemotherapy , eligible study Clofarabine / Intermediate-Dose Cytarabine ( CLARA ) versus High-Dose Cytarabine ( HDAC ) randomize 3 course CLARA chemotherapy 3 course HDAC chemotherapy consolidation . We compare efficacy toxicity among two arm .</brief_summary>
	<brief_title>The CLARA Study From Acute Leukemia French Association ( ALFA 0702 Trial )</brief_title>
	<detailed_description>Because result former trial ( ALFA-9802 ) [ Thomas , 2005 ] , chemotherapy combine arm G-CSF ( Granulocyte Colony-Stimulating Factor ) give sequence chemotherapy order increase blast priming .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Inclusion Criteria registration : 1 . Age 18 year less 60 year 2 . With : A morphologically proven diagnosis AML accord WHO classification , cytogenetically ( standard karyotype , FISHMLL ) molecularly ( FLT3 , CEBPA , NMP1 ) define . 3 . ECOG ( Eastern Cooperative Oncology Group ) performance status 0 2 . 4 . Have adequate renal hepatic function indicate follow laboratory value : Creatinine clearance ( calculate cockcroft Gault method ) ≥ 40mL/min ; AST ( Aspartate amino transférase ) ALT ( Alanine Amino Transférase ) &lt; = 2.5N ; total bilirubin &lt; = 2N ( unless relate underlying disease ) . 5 . Cardiac function determine radionuclide echography within normal limit . 6 . Women childbearing potential ( i.e . woman premenopausal surgically sterile ) must use acceptable contraceptive method , must negative serum urine pregnancy test within 2 week prior begin treatment trial . 7 . Must able willing give write informed consent . 8 . The subject must cover social security system . Exclusion Criteria registration : 1 . Patients AML favorable risk cytogenetics : M3AML ; CBFAML include ( 8:21 ) , inv ( 16 ) , ( 16 ; 16 ) AML . 2 . Phpositive AML . 3 . AML follow diagnosed myeloproliferation patient prior history MDS know 3 month 4 . Prior treatment chemotherapy radiotherapy another tumor . 5 . Prior tumor , stable least two year , except insitu carcinoma skin carcinoma 6 . Compromised organ function judge lifethreatening Investigator . 7 . Positive serology HIV ( Human Immunodeficiency Virus ) , HBV ( Hepatitis B Virus ) HBC ( Hepatitis C Virus ) ( except post vaccination ) 8 . Uncontrolled active infection kind bleeding . Patients infection active treatment antibiotic whose infection control may enter study . 9 . Other active malignancy . 10 . Patients concurrently receive standard investigational treatment leukemia , exception hydroxyurea . INCLUSION CRITERIA AT RANDOMIZATION 1 . Patients either first CR/CRp first induction course first CR/CRp salvage therapy . 2 . ECOG performance status 0 2 . 3 . AST ALT &lt; = 2.5N ; total bilirubin &lt; = 2N . 4 . Creatinine clearance ≥40mL/min ( calculate cockcroft Gault method MDRD ( see http : //nephron.org/cgibin/MDRD_GFR/cgi ) 5 . Patient without HLA identical donor . EXCLUSION CRITERIA AT RANDOMIZATION 6 . Patients belong intermediate 1 risk group ( CEBPA+ NPM1+ without Flt3ITD ) CR/CRp first induction course . These patient go study receive consolidation cycle base HDAraC ( Aracytine ) . 7 . Known central nervous system involvement AML . 8 . Uncontrolled active infection kind bleeding . 9 . Compromized organ function judge lifethreatening Investigator . 10 . Patient HLA identical donor identify .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Younger Patients Newly-Diagnosed Acute Myeloid Leukemia ( AML ) .</keyword>
</DOC>